SynCore Biotechnology Co Ltd (4192)

Currency in TWD
27.85
0.00(0.00%)
Delayed Data·
4192 Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
4192 is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
27.8527.85
52 wk Range
24.7041.00
Key Statistics
Bid/Ask
49.25 / 49.65
Prev. Close
32.8
Open
27.85
Day's Range
27.85-27.85
52 wk Range
24.7-41
Volume
-
Average Volume (3m)
6.89K
1-Year Change
-27.09%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
4192 Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Liquid assets exceed short term obligations

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Neutral
Moving Averages
Sell

SynCore Biotechnology Co Ltd Company Profile

SynCore Biotechnology Co.,Ltd, engages in development and sale of food advisory, medicine inspection, and biotechnology service in Taiwan. The company is involved in the development of SB01, an injectable anti-cancer new ingredient (NCE) that is in Phase II clinical trials for the treatment of head and neck cancer; and SB02, an anti-cancer NCE, which is in preclinical research for use in the treatment of stomach cancer. It also offers SB03-Veregen, an ointment for the treatment of patients with external genital and perianal warts EGW; and SB04, a conventional drug for the treatment of age-related macular degeneration dry AMD that is in Phase II/III clinical trials. In addition, the company provides SB05-EndoTAG-1, a conventional drug for pancreatic cancer and triple-negative breast cancer that is in Phase III clinical trials. Further, it distributes cameras under the epiCam name that is used in recording the progress of ophthalmology diseases. The company has partnerships with Medigene AG, MacuCLEAR Inc.; and Sinphar Pharmaceutical Co., Ltd.; and The National Health Research Institutes NHRI. SynCore Biotechnology Co.,Ltd was incorporated in 2008 and is headquartered in Yilan City, Taiwan. The company is a subsidiary of Sinphar Pharmaceutical Co., Ltd.

Compare 4192 to Peers and Sector

Metrics to compare
4192
Peers
Sector
Relationship
P/E Ratio
−17.9x−15.1x−0.5x
PEG Ratio
0.210.110.00
Price/Book
3.5x2.3x2.6x
Price / LTM Sales
40.2x5.6x3.3x
Upside (Analyst Target)
-0.0%43.5%
Fair Value Upside
Unlock−1.9%6.9%Unlock

Earnings

Latest Release
May 14, 2025
EPS / Forecast
-0.39 / --
Revenue / Forecast
5.39M / --
EPS Revisions
Last 90 days

4192 Income Statement

FAQ

What Stock Exchange Does SynCore BioTech Trade On?

SynCore BioTech is listed and trades on the Taipei Exchange stock exchange.

What Is the Stock Symbol for SynCore BioTech?

The stock symbol for SynCore BioTech is "4192."

What Is the SynCore BioTech Market Cap?

As of today, SynCore BioTech market cap is 979.33M.

What Is SynCore BioTech's Earnings Per Share (TTM)?

The SynCore BioTech EPS (TTM) is -1.55.

From a Technical Analysis Perspective, Is 4192 a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.

How Many Times Has SynCore BioTech Stock Split?

SynCore BioTech has split 2 times.

How Many Employees Does SynCore BioTech Have?

SynCore BioTech has 40 employees.

What is the current trading status of SynCore BioTech (4192)?

As of 07 Aug 2025, SynCore BioTech (4192) is trading at a price of 27.85, with a previous close of 32.80. The stock has fluctuated within a day range of 27.85 to 27.85, while its 52-week range spans from 24.70 to 41.00.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.